Bioventus Inc. Class A Common Stock (BVS) Stock
NASDAQ · BVS
12.91
Fundamentals
Market cap
$881.82M
Price / Earnings ratio
19.5x
Price / Sales ratio
1.8x
Price / Book ratio
4.7x
Return on assets
0.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Bioventus Inc. Class A Common Stock
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
SectorHealthcare
IndustryMedical Devices
Employees950
CEOMr. Robert E. Claypoole
IPO DateFeb 11, 2021
HeadquartersDurham, NC
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert E. Claypoole | President, CEO & Director | 1972 |
| Mr. Mark L. Singleton | Senior VP & CFO | 1969 |
| Mr. Anthony D'Adamio J.D. | Senior VP, General Counsel & Corporate Secretary | 1961 |
| Mr. Mike Crowe B.S., M.B.A. | Senior Vice President of Operations | — |
| Mr. David Crawford | Vice President of Investor Relations & Treasurer | — |
| Ms. Katrina J. Church J.D. | Senior VP & Chief Compliance Officer | 1962 |
| Ms. Helen Leupold | Senior VP & Chief Human Resources Officer | — |
| Mr. Dave Venner | Senior VP & GM of Surgical | — |
Fundamentals
Valuation
Market cap$881.82M
Price-to-sales ratio1.83
Price-to-book value4.65
Price-earnings ratio19.50
Return on Equity16.00%
Return on Sales0.09%
Return on Assets0.04%
PEG ratio1.53
Earnings Per Share
Earnings Per Share$0.81
Income Statement
Average volume530,790
EBITDA$97.24M
1 year high (52w)$15.89
1 year low (52w)$6.26
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



